Interestingly, the two studies reported contradictory results: Lin et al. (2024) study suggested a protective effect of SGLT2 inhibitors on prostate cancer, whereas Han et al. (2024) study indicated an increased risk. The gene discussed is SLC5A2; the disease is prostate cancer.